Basis: FMP quote price / unrounded diluted EPS from four consecutive issuer fiscal quarters. Source: stored company filings and market data; unavailable inputs remain N/A.
The P/E ratio is N/A as of 2026-10-06T18:57:44.474Z.
Calculation as of: 2026-10-06T18:57:44.474Z.
Quote observation: 2026-10-06T18:55:06.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 270619a8cb927235a94e92f97c71cdfb8fe28fc97d8c39ede642bd89729a24e3
PE RATIO
N/A
Mobile-health Network Solutions Class A Ordinary Shares
Market Cap
$30263.00
PE Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$6001.00
PE Ratio
N/A
TTM Avg
3571.19
3Y Avg
5980.81
5Y Avg
5980.81
| NAME | MARKET CAP | PE RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Mobile-health Network Solutions Class A Ordinary Shares (MNDR) | $30263.00 | N/A | N/A | N/A | N/A |
| Zhongchao Inc. (ZCMD)vs › | $31083.00 | N/A | N/A | N/A | N/A |
| NewGenIvf Group Limited (NIVF)vs › | $6001.00 | N/A | 3571.19 | 5980.81 | 5980.81 |
| Akanda Corp. (AKAN)vs › | $61819.00 | N/A | N/A | N/A | N/A |
| PRF Technologies Ltd. (PRFX)vs › | $70876.00 | N/A | N/A | N/A | N/A |
| Psyence Biomedical Ltd. (PBM)vs › | $96215.00 | N/A | N/A | N/A | N/A |
| Silexion Therapeutics Ltd. (SLXN)vs › | $108771.00 | N/A | N/A | N/A | N/A |
| SciSparc Ltd. (SPRC)vs › | $242924.00 | N/A | N/A | N/A | N/A |
| Virax Biolabs Group Limited (VRAX)vs › | $352721.00 | N/A | N/A | N/A | N/A |
| Niki BioSolutions, Inc. (NIKI)vs › | $381940.00 | N/A | N/A | N/A | N/A |
Trailing P/E
N/A
Forward P/E
N/A
PE Ratio = Share Price / Diluted EPS (TTM)
The price-to-earnings ratio measures how much investors pay for each dollar of trailing earnings. A lower PE can indicate a cheaper valuation; a higher PE implies higher growth expectations.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute